Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Summer;12(2):100-12.
doi: 10.1111/j.1527-3458.2006.00100.x.

A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor

Lynne E Rueter  1 , Diana L Donnelly-Roberts, Peter Curzon, Clark A Briggs, David J Anderson, Robert S Bitner
Affiliations
Review

A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor

Lynne E Rueter et al. CNS Drug Rev. 2006 Summer.

Abstract

A-85380 [3-(2(s)-azetidinylmethoxy) pyridine] is a neuronal nicotinic acetylcholine receptor (nAChR) agonist that has been a useful tool in the investigation of the function of nAChRs in both preclinical and clinical studies. Amongst nAChR subtypes, A-85380 shows selectivity for the alpha(4)beta(2) vs. the alpha(7) or alpha(1)beta(1)deltagamma nAChRs. In functional in vitro cation flux assays, A-85380 is a potent and full agonist. A-85380 has a broad-spectrum analgesic profile with efficacy in acute, persistent, and neuropathic pain models. As demonstrated using selective nAChR antagonists or alpha(4) antisense, the alpha(4)beta(2) nAChR mediates the analgesic effects of A-85380. Interestingly, the site of action depends upon the type of pain as antinociception is mediated by descending inhibition into the spinal cord whereas anti-allodynia in neuropathic pain is mediated at both central and peripheral sites. Radiolabelled forms of A-85380 have been developed and shown to be safe for use in vivo in humans. In clinical studies using positron and photon emission tomography, marked decreases in alpha(4)beta(2) nAChRs have been seen in patients with Parkinson's and Alzheimer's disease. Although not developed as a therapeutic agent, A-85380 has proven to be an important component in the development of novel nAChR ligands for the treatment of pain and other disorders.

PubMed Disclaimer

References

    1. Abreo MA, Lin NH, Garvey DS, et al. Novel 2‐pyridyl ethers with subnanomolar affinity for central nicotinic acetylcholine receptors. J Med Chem 39;39: 817–825. - PubMed
    1. Anderson DJ, Campbell JE, Raszkiewicz, A , et al. B inding properties of [3H]A‐85380, a high‐affinity neuronal nicotinic acetylcholine receptor radioligand. Soc Neurosci Abstr 1995;21: 606.
    1. Bitner RS, Nikkel AL, Curzon P, Arneric SP, Bannon AW, Decker MW. Role of the nucleus raphe magnus in antinociception produced by ABT‐594: Immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. JNeurosci 1998;18: 5426–32. - PMC - PubMed
    1. Bitner RS, Nikkel AL, Curzon P, et al. R educed nicotinic receptor‐mediated antinociception following in vivo antisense knock‐down in rat. Brain Res 2000;871: 66–74. - PubMed
    1. Buckley MJ, Surowy C, Meyer M, Curzon P. Mechanism of action of A‐85380 in a animal model of depression. Prog Neuro-Psychopharmacol Biol Psychiatr 2004;28: 723–730. - PubMed